Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Retained Earnings (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Retained Earnings data on record, last reported at -$324.9 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 5.83% year-over-year to -$324.9 million; the TTM value through Dec 2025 reached -$324.9 million, down 5.83%, while the annual FY2025 figure was -$324.9 million, 5.83% down from the prior year.
  • Retained Earnings reached -$324.9 million in Q4 2025 per VRCA's latest filing, down from -$316.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1000.0 in Q2 2021 and bottomed at -$324.9 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$194.6 million, with a median of -$193.4 million recorded in 2023.
  • The widest YoY moves for Retained Earnings: up 99.94% in 2022, down 15759900.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$29000.0 in 2021, then crashed by 563531.03% to -$163.5 million in 2022, then tumbled by 40.99% to -$230.4 million in 2023, then plummeted by 33.23% to -$307.0 million in 2024, then dropped by 5.83% to -$324.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$324.9 million in Q4 2025, -$316.8 million in Q3 2025, and -$316.6 million in Q2 2025.